InvestorsObserver
×
News Home

The Joint Corp Up 38.07% To $12.62 After Earnings Miss

Friday, March 08, 2024 10:16 AM | InvestorsObserver Analysts

Mentioned in this article

The Joint Corp Up 38.07% To $12.62 After Earnings Miss

The Joint Corp (JYNT) said after close Thursday that it lost $0.75 per share in quarter four 2023.

On the revenue line, the company reported $30.6 million, beating estimates by $1.5 million.

In the same quarter a year ago, the company earned $0.04 per share on revenue of $27.8 million.

The stock is up 38.07% to $12.62 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Wall Street Analysts had an average rating of Buy on the stock prior to the report.

Trading in the five days leading up to the report earned The Joint Corp a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 37. Meanwhile, the average Wall Street analyst rated the stock a Buy.

The Joint Corp. develops, owns, operates, supports, and manages chiropractic clinics through direct ownership, management arrangements, franchising, and regional developers throughout the United States. The Company operates through two segments. The Corporate Clinics segment is comprised of the operating activities of the Company-owned or managed clinics. The Company operates or manages approximately 126 clinics under this segment. The Franchise Operations segment is comprised of the operating activities of the franchise business unit. The franchise system consisted of approximately 712 clinics in operation. It offers a range of membership and wellness packages. It offers its patients the opportunity to visit its clinics without an appointment and receive prompt attention. Each patient's records are digitally updated for ready retrieval in its data storage system by its chiropractors in compliance with various applicable medical records security and privacy regulations.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App